SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Ultragenyx Pharmaceutical, Inc. is a biopharmaceutical company, which engages in the identification, acquisition, development, and commercialization of novel products for the treatment of genetic diseases. Its products include Crysvita, Mepsevii, Dojolvi, and Evkeeza. The company was founded by Emil D. Kakkis in April 2010 and is headquartered in Novato, CA.

Ultragenyx Pharmaceutical Inc.

Ultragenyx Pharmaceutical Inc

FDA approval of UX111, the first gene therapy for Sanfilippo syndrome type A, is driving attention, with traders highlighting a new commercial asset and potential priority-review voucher. The community is broadly bullish but debating the muted share-price reaction, launch economics, and whether short covering or further company guidance is needed to support a stronger rerating.

ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in San Diego, CA.

ImmunityBio Inc

A sharp, high-volume move without a confirmed IBRX-specific announcement has traders focused on technical breakout potential, institutional accumulation, and possible short covering. Debate centers on whether the rally reflects momentum and options activity or speculation about pending Anktiva catalysts, including papillary bladder-cancer approval, lymphopenia data, and other regulatory updates, with some traders warning of another fade.

CoreWeave, Inc. engages in the powers of the creation and delivery of the intelligence that drives innovation. It offers a solution used by organizations of all sizes that require sophisticated AI computing, from the largest of enterprises to small, well-funded start-ups. The company was founded by Michael Intrator, Brian Venturo, Peter Salanki, and Brannin McBee on September 21, 2017 and is headquartered in Livingston, NJ.

CoreWeave Inc. - Ordinary Shares - Class A

CoreWeave Inc

CoreWeaves plan to raise capital through a multi-billion-dollar convertible-note offering and a potential 35-million-share ATM program has driven attention, with traders focused on dilution, leverage, and managements timing. Bulls argue the financing supports expansion amid higher-priced compute contracts and strong customer commitments, while bears view it as evidence of worsening capital needs and pressure on shareholders.

Advanced Micro Devices, Inc. engages in the semiconductor business. Its products include processors, accelerators, graphics, adaptive SoCs, FPGAs, and SOMs, and software, tools, and apps. The firm offers artificial intelligence, industries, workloads, and gaming solutions. The company was founded by W. J. Sanders III on May 1, 1969 and is headquartered in Santa Clara, CA.

Advanced Micro Devices Inc.

Advanced Micro Devices Inc

A sharp AI- and semiconductor-led rebound has pushed AMD into focus, with traders citing strong demand for AI compute, bullish options flow, and a potential short squeeze while largely treating the rate hike as priced in. Bears counter that the move is overextended and valuation is excessive, warning that further rate hikes or an AI-spending slowdown could trigger a pullback.

DraftKings, Inc. is a digital sports entertainment and gaming company, which engages in the provision of online sports betting, online casino, daily fantasy sports product offerings, DraftKings Marketplace, retail sportsbook, media, and other consumer product offerings. The company was founded by Jason D. Robins, Matthew Kalish, and Paul Liberman on December 31, 2011 and is headquartered in Boston, MA.

DraftKings Inc. - Ordinary Shares - Class A

DraftKings Inc

A Ninth Circuit ruling that states can regulate Kalshi-style sports contracts as gambling, rather than federally regulated swaps, is drawing attention as a potential competitive and regulatory win for DraftKings ahead of football season. Traders remain divided over whether the decision meaningfully benefits DKNG, given ongoing appeals, prediction-market uncertainty, and concerns about profitability, dilution, and management execution.

Generac Holdings, Inc. engages in the business of designing and manufacturing energy technology solutions. It operates under the Domestic and International segments. The Domestic segment includes the legacy Generac business and the acquisitions that are based in the United States and Canada. The International segment focuses on Generac business' Latin American export operations. The company was founded in 1959 and is headquartered in Waukesha, WI.

Generac Holdings Inc

A long-term Amazon agreement to supply backup generators for data centers has shifted Generacs narrative toward AI infrastructure and driven heavy bullish interest, with traders highlighting stronger multi-year revenue visibility and potential additional hyperscaler demand. The community is also debating profit-taking, warrant-related dilution, and whether the sharp gap higher will fade as the stock consolidates.

Intel Corp. engages in the design, manufacture, and sale of computer products and technologies. It delivers computer, networking, data storage, and communications platforms. The firm operates through the following segments: Client Computing Group (CCG), Data Center and AI (DCAI), Intel Foundry Services (IFS), and All Other. The CCG segment consists of platforms designed for notebooks, 2-in-1 systems, desktops, tablets, phones, wireless and wired connectivity products, and mobile communication components. The DCAI segment delivers solutions to cloud service providers and enterprise customers, along with silicon devices for communications service providers and high-performance computing customers. The IFS segment refers to full stack solutions created from the foundry industry ecosystem. The All Other segment represents results from other non-reportable segments and corporate-related charges. The company was founded by Robert Norton Noyce and Gordon Earle Moore on July 18, 1968, and is headquartered in Santa Clara, CA.

Intel Corp.

Intel Corp

Reports that SK Hynix is in exploratory talks with Intel to potentially manufacture memory chips at Intels Ohio facility, or through a joint venture, are driving attention and bullish speculation around Intels foundry strategy. Traders are debating whether the potential partnership could improve Ohios economics and support a turnaround, while emphasizing that SK Hynix has said no agreement has been finalized and warning that the rally may fade if talks do not progress.

Snap, Inc. is a technology company, which engages in the provision of a visual messaging application that was created to help people communicate through short videos and images. The company was founded by Frank Reginald Brown IV, Evan Thomas Spiegel, and Robert C. Murphy in 2010 and is headquartered in Santa Monica, CA.

Snap Inc - Ordinary Shares - Class A

Snap Inc

Snaps launch of its Specs augmented-reality glasses, Specs Intelligence AI assistant, and enterprise partnerships has driven attention. Traders are divided between those viewing the technology as a major computing opportunity and skeptics who cite the glasses high price, limited demand visibility, repeated sell-the-news fades, and distrust of management.

GameStop Corp. engages in offering games and entertainment products through its ecommerce properties and stores. The firm’s stores and ecommerce sites operate primarily under the names GameStop, EB Games, and Micromania. It operates through the following geographical segments: United States, Canada, Australia, and Europe. The company was founded by Daniel A. DeMatteo in 1996 and is headquartered in Grapevine, TX.

Gamestop Corporation - Ordinary Shares - Class A

GameStop Corp

A sustained move higher has drawn attention to GameStop, with traders speculating that share repurchases or insider buying are behind the steady demand and that call-option positioning could add gamma and short-squeeze pressure. Bullish traders expect further momentum, while skeptics point to low volume, range-bound trading, and the lack of a confirmed company announcement.

Abeona Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development of gene therapy for severe and life-threatening rare diseases. It programs include EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB), ABO-102 (AAV-SGSH), an adeno-associated virus (AAV) based gene therapy for Sanfilippo syndrome type A (MPS IIIA), and ABO-101 (AAV NAGLU), an AAV based gene therapy for Sanfilippo syndrome type B (MPS IIIB). The company was founded in 1974 and is headquartered in Cleveland, OH.

Abeona Therapeutics Inc

Abeonas Q2 results and ZEVASKYN launch execution are driving attention, with revenue recognized for fewer treatments than completed after a manufacturing batch fell below the billing threshold and treatment-center ramping remained slow. Traders are split between viewing the issue as a temporary operational setback with expanding centers and future UX111 optionality, versus warning that delayed patient throughput and cash burn undermine near-term profitability.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Is CRBP a Good Cannabis Investment After Positive Obesity Study Data?

Corbus Pharmaceuticals' positive obesity data boosts its cannabinoid strategy, while CRB-701 and cash needs add key context for investors.

Sanofi To Receive 26.4% Stake In Cheplapharm For Mature Medicines

(RTTNews) - Sanofi (SNY, SAN.PA), a healthcare company, on Monday announced an agreement with Cheplapharm to create a strategic partnership for its mature medicines portfolio...

AbbVie's Immunology Franchise: From Skyrizi & Rinvoq to What's Next

ABBV's Skyrizi and Rinvoq drives immunology growth, while new indications, acquisitions and partnerships build its next wave.

GSK's Specialty Medicines Drive Growth Amid Looming HIV Patent Cliff

GSK's Specialty Medicines are driving growth, but an approaching HIV patent cliff is pushing the company to accelerate its pipeline.

Here's Why You Should Add NRIX Stock to Your Portfolio Now

Nurix is developing bexobrutideg in CLL, while Roche's $2.3B deal and new studies support its potential in cancer, immunology and neurology.

Does Moderna's mRNA Flu Shot Face a New Challenge From GSK?

MRNA's newly approved mFlusiva faces a potential challenge as GSK advances an mRNA flu vaccine targeting two viral proteins.

Eli Lilly to Buy Immunology Biotech Merida Biosciences in $2.9B Deal

LLY's $2.9B Merida deal adds immunology assets and expands its pipeline beyond obesity and diabetes into new growth areas.

NVAX Stock Climbs As Partnership Model Keeps COVID Vaccine Cash Flow Open  

Equity

Novavax said Sanofi and Takeda received clearances for an updated Nuvaxovid formulation for the 2026-2027 COVID season.

FDA Approves 3 New COVID-19 Vaccines

FDA Approves 3 New COVID-19 Vaccines

 Authored by Zachary Stieber via The Epoch Times,

The Food and Drug Administration on Aug. 27 approved COVID-19 vaccines from Pfizer, Moderna, and Sanofi.
A nurse prepares to give a COVID-19 vaccine to a child in Denver, Colo., on Nov. 3, 2021...

Top Stock Reports for NVIDIA, ExxonMobil & HSBC

NVIDIA, ExxonMobil and HSBC see growth from AI demand, energy expansion and Asia wealth momentum, but face distinct execution and market risks.

Sanofi engages in the research, production, and distribution of pharmaceutical products. It operates through the Biopharma segment, which comprises commercial operations and research, development and production activities relating to the specialty care, general medicines and vaccines franchises plus support and corporate functions, for all geographical territories. The company was founded in 1973 and is headquartered in Paris, France.

Sanofi - ADR

Neutral Sentiment

No more this year

One more

Two more

The Federal Reserve raised interest rates by a quarter point to a range of 3.75%-4.00% on Wednesday, its first hike since July 2023, but Fed Chair Kevin Warsh signaled the tightening cycle isn't over. How many more rate hikes do you expect by the end of 2026? Vote and explain your reasoning in the comments.

The Fed hiked rates 25bps yesterday, its first since 2023, but signaled it&#39;s not done - projections point to one or two more hikes this year. How many total hikes do you expect by year-end?

Stocktwits

The Fed hiked rates 25bps yesterday, its first since 2023, but signaled it's not done - projections point to one or two more hikes this year. How many total hikes do you expect by year-end?

Feed

News

Sentiment

Earnings

Fundamentals

Info

SNY Sanofi-Aventis

Fundamentals

Latest SNY News